Supporting Information:

Cerium oxide nanoparticles attenuate monocrotaline induced right ventricular hypertrophy

following pulmonary arterial hypertension

*Madhukar B. Kolli^{1,2}, *Nandini D.P.K. Manne^{1,2}, Radhakrishna Para², Siva K. Nalabotu ^{1,2}, Geeta Nandyala², Tolou Shokuhfar⁶, Kun He^{6,7}, Azhang Hamlekhan⁶, Ma J.Y⁴, Paulette S. Wehner³, Lucy Dornon³, Ravikumar Arvapalli², Kevin M. Rice², and Eric R. Blough^{1,2,5}

- ¹Department of Pharmacology, Physiology and Toxicology, Marshall University, Joan C. Edwards School of Medicine
- ²Center for Diagnostic Nanosystems, Marshall University, Huntington, WV, United States
- ³Department of Cardiology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV
- ⁴ Health Effects Laboratory Division, NIOSH, Morgantown, WV
- ⁵ Department of Pharmaceutical Sciences and Research, Marshall University
- ⁶Department of Mechanical Engineering and Engineering Mechanics, Michigan Technological University, Houghton, MI, USA.
- ⁷School of Materials Science and Engineering, Shandong University, Ji'nan, China


Author for correspondence:
Eric Blough
Center for Diagnostic Nanosystems
Room 241R, Robert C. Byrd Biotechnology Science Center Building
Department of Pharmaceutical Science and Research
1700 3rd Ave.
Marshall University
Huntington, WV 25755-1090
E-mail: blough@marshall.edu

Ph.No- 304-696-2708 Fax No- 304-696-3766

^{*} Authors contributed equally

SUPPLEMENTAL MATERIAL

Supplementary Figure 1



Supplementary Figure 1. Cerium oxide nanoparticles attenuate monocrotaline-induced serum inflammatory proteins.